Joyce A. Goldstein

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

P. Dayer, J. Goldstein, S. Benhamou, 1999, The Journal of pharmacology and experimental therapeutics.

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

P. Dayer, J. Goldstein, U. Meyer, 1998, The Journal of pharmacology and experimental therapeutics.

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

P. Dayer, J. Goldstein, S. Benhamou, 1998, Pharmacogenetics.

Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.

K Chiba, H. Yamazaki, N. Ozawa, 1998, Biochemical pharmacology.

Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.

J. Goldstein, J A Goldstein, J. Lasker, 1996, Drug metabolism and disposition: the biological fate of chemicals.

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

J. Goldstein, T. Edeki, R S Kidd, 2001, Pharmacogenetics.

Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular Tissues

J. Goldstein, J. Foley, D. Zeldin, 2007, Drug Metabolism and Disposition.

Expression of CYP1A1 and CYP1A2 genes in human liver.

S. Kitareewan, J. Goldstein, D. Nagorney, 1993, Pharmacogenetics.

Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.

J. Goldstein, M. Wester, B. Ghanayem, 2001, Biochemistry.